# Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma

> **NCT00245089** · PHASE2 · UNKNOWN · sponsor: **Japan Rhabdomyosarcoma Study Group** · enrollment: 41 (estimated)

## Conditions studied

- Sarcoma

## Interventions

- **BIOLOGICAL:** dactinomycin
- **DRUG:** cyclophosphamide
- **DRUG:** vincristine sulfate

## Key facts

- **NCT ID:** NCT00245089
- **Lead sponsor:** Japan Rhabdomyosarcoma Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-05
- **Primary completion:** 2011-04
- **Final completion:** —
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2013-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00245089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00245089, "Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00245089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*